Neurelis Drug Patent Portfolio
Neurelis owns 1 orange book drug protected by 11 US patents Given below is the list of Neurelis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12324852 | Administration of benzodiazepine compositions | 16 Oct, 2032 | Active |
| US12337061 | Administration of benzodiazepine compositions | 13 Jun, 2032 | Active |
| US11241414 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US11793786 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US12268664 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US12521400 | 27 Mar, 2029 | Active | |
| US8895546 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US9763876 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US8927497 | Absorption enhancers for intranasal administration | 21 Jul, 2025 | Expired |
| US10265402 | Absorption enhancers for drug administration | 11 May, 2025 | Expired |
| US9642913 | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent | 11 May, 2025 | Expired |
Latest Legal Activities on Neurelis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Neurelis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Request for Trial Granted | 16 Sep, 2025 | US8895546 |
| Request for Trial Granted | 16 Sep, 2025 | US11241414 |
| Request for Trial Granted | 16 Sep, 2025 | US11793786 |
| Mail O.P. Petition Decision | 11 Sep, 2025 | US12337061 |
| Email Notification | 11 Sep, 2025 | US12337061 |
| Mail-Petition Decision - Granted | 09 Sep, 2025 | US12337061 |
| O.P. Petition Decision | 08 Sep, 2025 | US12337061 |
| Petition Decision - Granted | 08 Sep, 2025 | US12337061 |
| Mail Examiner Interview Summary (PTOL - 413) | 05 Sep, 2025 | US12521400 |
| Email Notification | 05 Sep, 2025 | US12521400 |
| Interview Summary Record | 03 Sep, 2025 | US12521400 |
| Interview Summary - Applicant Initiated - Conference | 05 Aug, 2025 | US12521400 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jul, 2025 | US11241414 |
| Email Notification | 23 Jul, 2025 | US12337061 |
| Recordation of Patent eCertificate of Correction | 22 Jul, 2025 | US12337061 |
Neurelis's Drug Patent Litigations
Neurelis's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 29, 2019, against patent number US9763876. The petitioner Aquestive Therapeutics, Inc. formerly Monosol RX, LLC, challenged the validity of this patent, with Neurelis, Inc. as the respondent. Click below to track the latest information on how companies are challenging Neurelis's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11241414 | January, 2025 |
Trial Instituted
(16 Sep, 2025)
| Neurelis, Inc. | Padagis US LLC et al. |
| US11793786 | January, 2025 |
Trial Instituted
(16 Sep, 2025)
| Neurelis, Inc. | Padagis US LLC et al. |
| US8895546 | January, 2025 |
Trial Instituted
(16 Sep, 2025)
| Neurelis, Inc. | Padagis US LLC et al. |
| US9763876 | January, 2019 |
Final Written Decision
(06 Aug, 2020)
| Neurelis, Inc. | Aquestive Therapeutics, Inc. formerly Monosol RX, LLC |
| US9763876 | January, 2019 |
Institution Denied
(01 Aug, 2019)
| Neurelis, Inc. | Aquestive Therapeutics, Inc. formerly Monosol RX, LLC |
| US9763876 | January, 2019 |
Institution Denied
(01 Aug, 2019)
| Neurelis, Inc. | Aquestive Therapeutics, Inc. formerly Monosol RX, LLC |
Neurelis's Family Patents
Neurelis Drug List
Given below is the complete list of Neurelis's drugs and the patents protecting them.
1. Valtoco
Valtoco is protected by 11 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12324852 | Administration of benzodiazepine compositions |
16 Oct, 2032
(6 years from now)
| Active |
| US12337061 | Administration of benzodiazepine compositions |
13 Jun, 2032
(6 years from now)
| Active |
| US11241414 | Administration of benzodiazepine compositions |
27 Mar, 2029
(3 years from now)
| Active |
| US11793786 | Administration of benzodiazepine compositions |
27 Mar, 2029
(3 years from now)
| Active |
| US12268664 | Administration of benzodiazepine compositions |
27 Mar, 2029
(3 years from now)
| Active |
| US12521400 |
27 Mar, 2029
(3 years from now)
| Active | |
| US8895546 | Administration of benzodiazepine compositions |
27 Mar, 2029
(3 years from now)
| Active |
| US9763876 | Administration of benzodiazepine compositions |
27 Mar, 2029
(3 years from now)
| Active |
| US8927497 | Absorption enhancers for intranasal administration |
21 Jul, 2025
(7 months ago)
| Expired |
| US10265402 | Absorption enhancers for drug administration |
11 May, 2025
(10 months ago)
| Expired |
| US9642913 | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent |
11 May, 2025
(10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valtoco's drug page